SK Plasma - About the company
SK Plasma is a funded company based in Seongnam-si (South Korea), founded in 1970. It operates as a Manufactures plasma derivatives. The company has 114 active competitors, including 30 funded and 15 that have exited. Its top competitors include companies like Bit.bio, Cellply and Kiyatec.
Company Details
Skplasma produces plasma derivatives by processing, fractionating, and purifying the plasma. The product portfolio of the company includes albumin, Antithrombin III, immunoglobulin, and coagulation factor.
- Website
- skplasma.com
- Email ID
- *****@sk.com
Key Metrics
Founded Year
1970
Location
Seongnam-si, South Korea
Stage
Funding Raised
Investors
Ranked
9th among 114 active competitors
Employee Count
147 as on Sep 30, 2026
Investment & Acquisitions
Sign up to download SK Plasma's company profile
SK Plasma's funding and investors
SK Plasma is a funded company. SK Plasma has 1 institutional investor.
View details of SK Plasma's funding rounds and investors
SK Plasma's founders and board of directors
Founder? Claim ProfileSK Plasma's employee count trend
SK Plasma has 147 employees as of Sep 26. Here is SK Plasma's employee count trend over the years:
Uncover SK Plasma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
SK Plasma's Competitors and alternates
Top competitors of SK Plasma include Bit.bio, Cellply and Kiyatec. Here is the list of Top 10 competitors of SK Plasma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Bit.bio 2016, Cambridge (United Kingdom), Series C | Manufacturer of programmed human cells for research and drug discovery | $266M | 67/100 | |
2nd | Developer of in-vitro diagnostic products for the detection of cancer | $16.4M | 60/100 | ||
3rd | Kiyatec 2005, Pendleton (United States), Series C | Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to cancer drug treatment | $29.5M | 55/100 | |
4th |  CytoTronics 2015, Boston (United States), Series A | Developer of cell-based assays for drug discovery | $22.8M | 55/100 | |
5th | Developer of 3D cell culture products for drug discovery | $4.1M | 50/100 | ||
6th | Pelago Bioscience 2013, Solna (Sweden), Seed | Assay services for use in the determination and quantification of drug-target interactions | - | 48/100 | |
7th |  Cytotheryx 2018, Rochester (United States), Series A | Developer of human hepatocytes for research and clinical applications | $60M | 47/100 | |
8th | StemBioSys 2010, San Antonio (United States), Series A | Cell culture technology company advancing regenerative medicine and drug discovery | $14.5M | 45/100 | |
9th | SK Plasma 1970, Seongnam-si (South Korea), Funding Raised | Manufactures plasma derivatives | - | 45/100 | |
10th |  Nanocrine 2018, Frederick (United States), Seed | Provider of a cell analysis and drug design tool for researchers | $300K | 43/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on SK Plasma's competitors? Click here to see the top ones
SK Plasma's Investments and acquisitions
SK Plasma has a total of 1 investment in Curocell. SK Plasma has not made any acquisitions as of now.Reports related to SK Plasma
Here is the latest report on SK Plasma's sector:
News related to SK Plasma
Filter this listMedia has covered SK Plasma for 1 event in last 1 year, It was about company updates.
•
SK Plasma Breaks Ground on Plasma Therapeutics Plant in TurkeyThe Korea Times•Jun 15, 2026•SK Plasma
•
•
SK Plasma Secures Exclusive Distribution Deal with Janssen Korea for Velcade InjectionBusinesskorea•Dec 16, 2024•Janssen Pharmaceutica, SK Plasma
•
TiumBio Sells SK Plasma Shares to Hahn & Company for Strategic R&D FundingBusinesskorea•Nov 18, 2024•TiumBio, SK Plasma
•
SK Plasma Secures Investment from Indonesian Sovereign Wealth FundBusinesskorea•Nov 15, 2024•SK Plasma
•
SK plasma ships 1st batch of $11.3 million contract manufacturing blood products to SingaporeKBR•Dec 14, 2023•SK Plasma
•
SK Plasma gets investment from Indonesian fundKedglobal•Oct 10, 2023•SK Plasma, Indonesia Investment Authority
•
•
SK Plasma to break ground for its new blood product plant in Indonesia in MayKBR•Mar 24, 2023•SK Plasma
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about SK Plasma
Explore our recently published companies
- Syndicate Finance - Mumbai based, 1977 founded, Unfunded company
- Triveni Chemicals - Vapi based, 1985 founded, Unfunded company
- Longplay - 2026 founded, Unfunded company
- Lala Lajpat Rai College of Commerce and Economics - Mumbai based, 1972 founded, Unfunded company
- Healthcare in - Germany based, Unfunded company
- TYT Studio - Ahmedabad based, 2015 founded, Unfunded company
